Poly-MVA® and prostate health: Shari Lieberman PhD, CNS, FACN discusses cancer case studies with the Foundation for Advancement in Cancer Research

Townsend Letter for Doctors and Patients, August-Sept, 2006

FACR: So, what does this say about this particular case and others that you have seen?

Dr Lieberman: While this case used conventional treatments, it provides compelling evidence that this formulation would likely be worthwhile for people with lung and other forms of cancer if they included it in their regiment. This is an excellent case study demonstrating Poly-MVA as an integrative approach for the treatment of NSCLC.

FACR: Would you like to make any other comments about Poly-MVA to sum up this discussion?

Dr. Lieberman: Yes. The lipoic acid palladium compound found in Poly-MVA is a novel substance. It has shown great promise, not only as adjuvant support for patients with a variety of different cancers, but as daily support for everyone because of its basic antioxidant and protective capabilities, I believe it is something we all should be taking on a daily basis, not just when we need it most. Dr. Frank Antonawich also has investigated it for its ability to support and protect cerebrovascular health. He is currently involved in an exciting new study titled, "Poly-MVA Utilized in Neuroprotection for Chronic Hypertension (PUNCH)." I am eagerly awaiting the results of this and future studies on this interesting formulation.

The information in this article is not intended to provide personal medical advice, which should be obtained from a medical professional, and has not been approved by the US FDA.